Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Curr Opin HIV AIDS. 2011 Jan;6(1):80-5. doi: 10.1097/COH.0b013e3283412515.
HIV-infected cells persisting in the face of highly active antiretroviral therapy are arguably the greatest hurdle to eradication of the virus from the body. Complementary strategies aimed at selective killing of infected cells are described.
Pioneered by research in the cancer field, various approaches are under development for selective killing of HIV-infected cells. These include targeted cytotoxic proteins, adoptive cell therapy, cytocidal virotherapy, and targeted nonbiological drug carriers.
These developmental efforts may provide a critical complement to antiretroviral therapy in efforts to achieve HIV eradication, or a 'functional cure' whereby therapy can be stopped without viral rebound.
在高效抗逆转录病毒疗法的作用下，持续存在的受 HIV 感染的细胞是从体内清除病毒的最大障碍。本文介绍了旨在选择性杀伤受感染细胞的补充策略。
受癌症领域研究的推动，目前正在开发各种选择性杀伤 HIV 感染细胞的方法。这些方法包括靶向细胞毒性蛋白、过继细胞疗法、溶细胞病毒疗法和靶向非生物药物载体。
这些发展中的努力可能为实现 HIV 清除（即“功能性治愈”）提供关键补充，从而无需病毒反弹即可停止治疗。
